- Home
- KURA vs CLVT Comparison
KURA vs CLVT Comparison
Compare KURA & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | CLVT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KURA | CLVT |
|---|---|---|
| Price | $10.91 | $1.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $25.56 | $3.22 |
| AVG Volume (30 Days) | 1.8M | ★ 3.9M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | N/A | ★ N/A |
| Revenue | $67,482,000.00 | ★ $974,345,000.00 |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $106.37 | $2.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | 0.61 |
| 52 Week Low | $7.36 | $1.66 |
| 52 Week High | $13.90 | $3.96 |
Technical Indicators
Market Signals| Indicator | KURA | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 43.70 |
| Support Level | $8.45 | $1.79 |
| Resistance Level | $11.40 | $2.07 |
| Average True Range (ATR) | 0.48 | 0.09 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 6.75 | 14.75 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.